Study #2022-0356
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered with Membrane Bound IL15 Plus Acetazolamide in Adult Patients with Metastatic Melanoma
MD Anderson Study Status
Not Accepting
Treatment Agent
OBX-115, Acetazolamide, Cyclophosphamide, Furosemide, Mesna, Fludarabine Phosphate
Description
The goal of this clinical research study is to find the recommended dose of OBX-115 in combination with acetazolamide that can be given to patients with metastatic melanoma previously treated with immune checkpoint inhibitors. The safety and tolerability of the study drug combination will also be studied.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Tumor, Metastatic Melanoma, Melanoma
Study phase:
Phase I
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.